TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma.
Erazo T, Evans CM, Zakheim D, Chu EL, Refermat AY, Asgari Z, Yang X, Da Silva Ferreira M, Mehta S, Russo MV, Knezevic A, Zhang XP, Chen Z, Fennell M, Garippa R, Seshan V, de Stanchina E, Barbash O, Batlevi CL, Leslie CS, Melnick AM, Younes A, Kharas MG.
Erazo T, et al. Among authors: fennell m.
Nat Commun. 2022 Sep 27;13(1):5676. doi: 10.1038/s41467-022-33137-8.
Nat Commun. 2022.
PMID: 36167829
Free PMC article.